122 related articles for article (PubMed ID: 38450658)
1. Cytotoxic monastrol derivatives as adjective inhibitors of drug-resistant Eg5: a molecular dynamics perspective.
Shahabipour S; Shamkhali AN; Razzaghi-Asl N
J Biomol Struct Dyn; 2024 Mar; ():1-14. PubMed ID: 38450658
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol.
Maliga Z; Mitchison TJ
BMC Chem Biol; 2006 Feb; 6():2. PubMed ID: 16504166
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
[TBL] [Abstract][Full Text] [Related]
4. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
Maliga Z; Kapoor TM; Mitchison TJ
Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
[TBL] [Abstract][Full Text] [Related]
5. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
[TBL] [Abstract][Full Text] [Related]
6. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
[TBL] [Abstract][Full Text] [Related]
7. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
8. Monastrol inhibition of the mitotic kinesin Eg5.
Cochran JC; Gatial JE; Kapoor TM; Gilbert SP
J Biol Chem; 2005 Apr; 280(13):12658-67. PubMed ID: 15665380
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening.
Zhang W; Zhai L; Lu W; Boohaker RJ; Padmalayam I; Li Y
Chem Biol Drug Des; 2016 Aug; 88(2):178-87. PubMed ID: 26864917
[TBL] [Abstract][Full Text] [Related]
10. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Biphenyl-Type Inhibitors Targeting the Eg5 α4/α6 Allosteric Pocket.
Gao C; Lowndes NF; Eriksson LA
ACS Omega; 2017 May; 2(5):1836-1849. PubMed ID: 30023646
[TBL] [Abstract][Full Text] [Related]
12. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.
Garcia-Saez I; DeBonis S; Lopez R; Trucco F; Rousseau B; Thuéry P; Kozielski F
J Biol Chem; 2007 Mar; 282(13):9740-9747. PubMed ID: 17251189
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
Makala H; Ulaganathan V
J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
[TBL] [Abstract][Full Text] [Related]
14. MD simulation-based screening approach identified tolvaptan as a potential inhibitor of Eg5.
Sebastian J; Raghav D; Rathinasamy K
Mol Divers; 2023 Jun; 27(3):1203-1221. PubMed ID: 35789974
[TBL] [Abstract][Full Text] [Related]
15. Small molecule allosteric uncoupling of microtubule depolymerase activity from motility in human Kinesin-5 during mitotic spindle assembly.
Kim CD; Kim ED; Liu L; Buckley RS; Parameswaran S; Kim S; Wojcik EJ
Sci Rep; 2019 Dec; 9(1):19900. PubMed ID: 31882607
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the interaction of the Eg5 Loop5 with the nucleotide site.
Harrington TD; Naber N; Larson AG; Cooke R; Rice SE; Pate E
J Theor Biol; 2011 Nov; 289():107-15. PubMed ID: 21872609
[TBL] [Abstract][Full Text] [Related]
17. ATPase mechanism of Eg5 in the absence of microtubules: insight into microtubule activation and allosteric inhibition by monastrol.
Cochran JC; Gilbert SP
Biochemistry; 2005 Dec; 44(50):16633-48. PubMed ID: 16342954
[TBL] [Abstract][Full Text] [Related]
18. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.
Kapoor TM; Mayer TU; Coughlin ML; Mitchison TJ
J Cell Biol; 2000 Sep; 150(5):975-88. PubMed ID: 10973989
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
Peters T; Lindenmaier H; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):291-9. PubMed ID: 16365780
[TBL] [Abstract][Full Text] [Related]
20. Insights into the Molecular Mechanisms of Eg5 Inhibition by (+)-Morelloflavone.
Ogunwa TH; Laudadio E; Galeazzi R; Miyanishi T
Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 30995725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
